Effect of Single Event Multi Level Chemoneurolysis with AbobotulinumtoxinA (Dysport) on Energy Expenditure and Walking Efficiency in Children with Cerebral Palsy
Sponsor: |
Ipsen Pharmaceuticals |
Enrolling: |
Male and Female Patients |
Clinic Visits: |
4 |
IRB Number: |
AAAR1322 |
U.S. Govt. ID: |
NCT03469999 |
Contact: |
Nancy Lee: 2123059416 / nl2674@columbia.edu |
This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the a botulinum toxin A drug, Dysport, on walking energy expenditure and gait in children with spastic diplegia Cerebral Palsy.
This study is closed
Investigator
Heakyung Kim, MD
Is your child between the ages of 5 and 17 years old? |
Yes |
No |
Is your child over 45lbs? |
Yes |
No |
Is your child able to walk with or without an assistive device? |
Yes |
No |
Does your child have stiff/spastic legs? |
Yes |
No |